By Steve Moore | Monday 18 October 2021
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Biopharmaceutical data analytics company IXICO (IXI) has made a trading update including that year ended 30th September 2021 EBITDA is “expected to be materially ahead of market expectations of £1.2 million and prior year (2020: £1.3 million)”. Why then is the share price little changed at circa 84.5p?…